南京市2019~2021年各类止血药物使用情况分析

Analysis of the use of various hemostatic drugs in Nanjing from 2019 to 2021

目的 了解南京市2019~2021年各类止血药的应用特点与趋势。方法 对南京市2019~2021年临床用止血药的销售金额、用药频度(DDDs)、限定日费用(DDDc)等进行回顾统计分析。结果 2019~2021年临床用止血药用药金额排序位居前列的是作用于血管的药物和凝血酶类止血药。单项用药金额增长最快的为纤维蛋白原。DDDs排序靠前的止血药是生长抑素、蛇毒血凝酶(速乐涓)、氨甲环酸(止血环酸)、尖吻蝮蛇血凝酶(苏灵)。DDDs增长最快的止血药为氨甲苯酸;DDDc最高的药物为凝血酶原复合物。因药物价格下调,所有止血药物DDDc均有不同程度的波动。结论 患者应用止血药以促进凝血、收缩血管功能药为主,尤其是作用于血管类药物,抗纤溶药近3年DDDs变动较大,应加强外科围手术期止血药临床合理使用。

Objective To understand the application characteristics and trends of various hemostatic drugs in Nanjing from 2019 to 2021.Methods A retrospective analysis was performed on the sales amount,DDDs and DDDc of clinical applied hemostatic drugs in Nanjing from 2019 to 2021.Results From 2019 to 2021,the top ranking sales amount of clinical applied hemostatic drugs were the drugs Drugs acting on the blood vessels and thrombin hemostatic drugs,the sales amount of fibrinogen ranked first.The hemostatic drugs which DDDs ranked first were somatostatin,snake venom hemocoagulase(Sulejuan),tranexamic acid(hemostatic acid),and viper hemocoagulase(Su Ling).The fastest growing hemostatic drug for DDDs was aminoacetic acid;the hemostatic drug with the highest DDDc was prothrombin complex.All hemostatic drug DDDc fluctuated to varying degrees due to drug price reduction.Conclusion Hemostatic drugs used by patients are mainly functional drugs that promote coagulation and constriction of blood vessels,especially those that act on blood vessels.DDDs of anti-fibrinolytic drugs have changed greatly in recent 3 years,and clinical rational use of perioperative hemostatic drugs should be strengthened.